NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
Clinical Trials
34 trialsNCT03363373 2026-02-19
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Y-mAbs Therapeutics
Phase 2 Recruiting
NCT04229979 2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3 Active not recruiting
NCT01903330 2025-03-05
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Epitopoietic Research Corporation
Phase 2 Active not recruiting
NCT02078648 2025-02-03
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Stemline Therapeutics, Inc.
Phase 1/2 Completed
NCT01784913 2024-12-16
UV1/hTERT2012P
Ultimovacs ASA
Phase 1/2 Completed
NCT01789099 2024-12-16
UV1-hTERT2012L
Ultimovacs ASA
Phase 1/2 Completed
NCT02275416 2024-12-16
Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma
Ultimovacs ASA
Phase 1/2 Completed
NCT01266083 2024-11-19
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Sellas Life Sciences Group
Phase 2 Completed
NCT03761914 2024-11-19
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sellas Life Sciences Group
Phase 1/2 Completed
NCT01827137 2024-09-19
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
Sellas Life Sciences Group
Phase 1/2 Completed
NCT03538314 2024-08-22
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
Ultimovacs ASA
Phase 1 Completed
NCT02297698 2023-12-12
HER3+
Cancer Insight, LLC
Phase 2 Completed
NCT05238558 2023-09-21
Safety and Immune Response to FMPV-1
Hubro Therapeutics AS
Phase 1 Completed
NCT06047535 2023-09-21
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.
SciClone Pharmaceuticals
Phase 4 Not yet recruiting
NCT04584112 2023-03-15
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT02978222 2022-12-15
Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
Marker Therapeutics, Inc.
Phase 2 Terminated
NCT04861948 2022-10-04
IBI188 Combination Therapy in Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Terminated
NCT04909515 2022-09-01
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.
Y-mAbs Therapeutics
Phase 2 Withdrawn
NCT05366062 2022-05-13
ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab
Epitopoietic Research Corporation
Phase 2 Not yet recruiting
NCT02873819 2022-03-08
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
Gliknik Inc.
Phase 2 Completed
NCT02383212 2020-01-27
Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Regeneron Pharmaceuticals
Phase 1 Completed
NCT01875653 2019-05-10
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
Lisata Therapeutics, Inc.
Phase 3 Terminated
NCT02149225 2018-08-07
GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Immatics Biotechnologies GmbH
Phase 1 Completed
NCT00458601 2018-01-16
ACT III
Celldex Therapeutics
Phase 2 Completed
NCT01480479 2018-01-16
ACT IV
Celldex Therapeutics
Phase 3 Completed
NCT01265901 2017-10-12
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Immatics Biotechnologies GmbH
Phase 3 Completed
NCT01909752 2017-07-06
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer
UbiVac
Phase 2 Completed
NCT01479244 2017-02-27
PRESENT
Galena Biopharma, Inc.
Phase 3 Completed
NCT00554372 2016-02-04
A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
SillaJen, Inc.
Phase 2 Completed
NCT01592045 2015-09-23
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
United Therapeutics
Phase 1/2 Completed
NCT00785122 2013-05-16
IMA910-101
Immatics Biotechnologies GmbH
Phase 1/2 Completed
NCT00969722 2013-03-08
A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients
United Therapeutics
Phase 2 Terminated
NCT00629759 2013-01-04
A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma
Jennerex Biotherapeutics
Phase 1 Completed